The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy

JSY Lau; JH McMahon; C Gubser; A Solomon; CYH Chiu; A Dantanarayana; S Chea; S Tennakoon; JM Zerbato; J Garlick; V Morcilla; S Palmer; SR Lewin; TA Rasmussen

Journal article

The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy

JSY Lau, JH McMahon, C Gubser, A Solomon, CYH Chiu, A Dantanarayana, S Chea, S Tennakoon, JM Zerbato, J Garlick, V Morcilla, S Palmer, SR Lewin, TA Rasmussen

AIDS | Published : 2021

DOI: 10.1097/QAD.0000000000002919

Abstract

Objective:The aim of this study was to quantify HIV-specific immunological and virological changes in people with HIV (PWH) on antiretroviral therapy (ART) with malignancy who received immune checkpoint blockade (ICB).Design:An observational cohort study.Methods:Blood samples were collected before and after four cycles of ICB in HIV-positive adults on ART. Virological assessments performed on CD4+T cells included cell-associated unspliced HIV RNA, cell-associated HIV DNA, Tat/rev-induced limiting dilution assay (TILDA) and plasma HIV RNA using a single copy assay (SCA). Flow cytometry was used to assess the frequency of precursor exhausted T cells (Tpex) and exhausted T cells (Tex), and Gag-..

View full abstract

University of Melbourne Researchers

Jillian Lau Author

Celine Gubser Author

Sharon Lewin Author

Thomas Rasmussen Author

Related Projects (4)

Effect of Immune Checkpoint Inhibitors on HIV Persistence: An observational study among HIV patients with cancer (The iCHIP Study)

Delaney AIDS Research Enterprise to Cure HIV - IRF3 Year 2 (Amendment 1) - Monash university research consultancy

Using immune checkpoint blockade to reinvigorate exhausted T cells in people living with HIV (PLWH) on antiretroviral therapy (ART)

ADDRESSING THE MAJOR CHALLENGES IN HIV VACCINE AND CURE RESEARCH

HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections ea..

Grants

Awarded by National Institute of Allergy and Infectious Diseases

Funding Acknowledgements

This work was supported by grants from the Foundation for AIDS Research (amfAR; grant number 109226-58RGRL), National Health and Medical Research Council (NHMRC; grant number GNT1149990), and the Melbourne HIV Cure Consortium (Rasmussen 2019), and The Australian Centre for HIV and Hepatitis Research to TAR (ACH2; Rasmussen 2019). J.S.Y.L is a postgraduate fellowand S.R.L. is a practitioner fellowof the Australian National Health and Medical Research Council. S.P. and V.M. were supported by the Delaney AIDS Research Enterprise (DARE) to Find a Cure (1UM1AI126611-01) and the Australian National Health and Medical Research Council (APP1149990).